Short Interest in AmpliPhi Biosciences (APHB) Expands By 9.7%

AmpliPhi Biosciences (NYSEAMERICAN:APHB) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,044,314 shares, a growth of 9.7% from the February 15th total of 952,070 shares. Approximately 39.4% of the shares of the company are short sold. Based on an average daily trading volume, of 337,121 shares, the days-to-cover ratio is currently 3.1 days.

In other news, Director Jeremy Curnock Cook bought 46,666 shares of AmpliPhi Biosciences stock in a transaction dated Thursday, November 22nd. The shares were bought at an average price of $7.40 per share, for a total transaction of $345,328.40. Following the purchase, the director now owns 330 shares of the company’s stock, valued at $2,442. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

How to Become a New Pot Stock Millionaire

Separately, HC Wainwright set a $6.00 target price on shares of AmpliPhi Biosciences and gave the company a “buy” rating in a research report on Thursday, March 15th.

Shares of APHB stock traded down $0.02 on Monday, reaching $1.09. The company had a trading volume of 313,200 shares, compared to its average volume of 723,907. AmpliPhi Biosciences has a 12 month low of $0.67 and a 12 month high of $5.00.

COPYRIGHT VIOLATION WARNING: “Short Interest in AmpliPhi Biosciences (APHB) Expands By 9.7%” was originally reported by Enterprise Leader and is the sole property of of Enterprise Leader. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://theenterpriseleader.com/2018/04/02/ampliphi-biosciences-aphb-short-interest-update.html.

AmpliPhi Biosciences Company Profile

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for AmpliPhi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmpliPhi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply